![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo PR Newswire VICTORIA, BC, July 8, 2024 VICTORIA, BC, July 8, 2024 /PRNewswire/ - Eupraxia...
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024 PR Newswire VICTORIA, BC, July 3...
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders PR Newswire VICTORIA, BC, June 6, 2024 VICTORIA, BC, June 6, 2024 /PRNewswire/ - Eupraxia...
Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024 PR Newswire VICTORIA, BC, June 5, 2024...
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Canada NewsWire VICTORIA, BC, May 23, 2024 Eight of nine patients...
Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024 Canada NewsWire VICTORIA, BC, May 22...
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR Newswire VICTORIA, BC, May 21, 2024 Trial's first...
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024 PR...
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire VICTORIA, BC, May 8, 2024 Eupraxia common shares now listed on the Nasdaq Capital...
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board PR Newswire VICTORIA, BC, May 2, 2024 --Advisory Board to Provide Guidance for Company's Eosinophilic Esophagitis...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.24 | -6.48648648649 | 3.7 | 3.7 | 3.32 | 8029 | 3.46106018 | CS |
4 | -0.24 | -6.48648648649 | 3.7 | 3.74 | 3.25 | 12249 | 3.51396518 | CS |
12 | -0.24 | -6.48648648649 | 3.7 | 4.1 | 3.25 | 16810 | 3.76858823 | CS |
26 | -1.81 | -34.3453510436 | 5.27 | 7.64 | 3.25 | 42520 | 4.42397001 | CS |
52 | -4.16 | -54.593175853 | 7.62 | 8.46 | 3.25 | 33005 | 5.24415385 | CS |
156 | -0.44 | -11.2820512821 | 3.9 | 9.1 | 0.8 | 26966 | 4.17128109 | CS |
260 | -4.29 | -55.3548387097 | 7.75 | 9.1 | 0.8 | 25756 | 4.25818758 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions